Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in December

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 952,300 shares, a growth of 14.4% from the December 15th total of 832,200 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average trading volume of 94,200 shares, the short-interest ratio is currently 10.1 days.

Insiders Place Their Bets

In other news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 16,054 shares of company stock worth $185,897. Company insiders own 19.52% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds have recently modified their holdings of GYRE. FMR LLC acquired a new position in Gyre Therapeutics during the third quarter worth about $47,000. Barclays PLC lifted its stake in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $123,000. Renaissance Technologies LLC purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $218,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Stock Up 1.4 %

NASDAQ GYRE traded up $0.15 during mid-day trading on Friday, hitting $10.95. The stock had a trading volume of 48,956 shares, compared to its average volume of 116,811. The firm’s 50 day moving average is $11.57 and its 200 day moving average is $12.64. Gyre Therapeutics has a twelve month low of $8.26 and a twelve month high of $26.37.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.